In a nutshell
This study reviewed the effectiveness and safety of vibegron in the treatment of overactive bladder (OAB). Researchers suggested that vibegron was associated with improved OAB symptoms and was well tolerated.
Some background
OAB consists of a frequent and sudden urge to urinate that may be difficult to control. It is present in 18.6% of the adult US population. The standard treatment for OAB was anticholinergics. However, the effectiveness of this therapy is limited and associated with side effects such as dry mouth and dizziness.
Vibegron is a novel agent. It works by decreasing the contraction of the bladder muscles so it can store more urine. Prior studies showed that this drug is associated with improved outcomes for patients with OAB. However, the studies to date had a limited number of participants.
Methods & findings
This study reviewed 3 other studies about vibegron in patients with OAB. It included information about 2120 patients with OAB overall. The doses of vibegron were 75 mg and 100 mg. Treatment lasted for 12 weeks.
Patients who received treatment with vibegron had significantly fewer urination episodes, including urgency urination compared to placebo. They also experienced fewer incontinence (leak of urine) events and a decreased urine volume when compared to placebo. The most common side effect was dry mouth.
The bottom line
This study concluded that vibegron is an effective and well tolerated treatment option for patients with OAB.
The fine print
This study evaluated vibegron in comparison with placebo. Its effectiveness and safety compared to other OAB drugs are still unknown. Also, the follow-up period was of 12 weeks. Longer-term studies are needed.
Published By :
Neurourology and urodynamics
Date :
May 18, 2020
